Dan Theodorescu

发表

Terahertz spectroscopic characterization of cancer cells

Dwight L. Woolard, Tatiana Globus, Tatyana Khromova, 2005, SPIE BiOS.

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy

Dan Theodorescu, D. Theodorescu, K. Felsenstein, 2018, Nature Reviews Urology.

Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.

Garrett M. Dancik, Dan Theodorescu, D. Theodorescu, 2012, Cancer research.

Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey.

Dan Theodorescu, D. Theodorescu, Joshua D Hall, 2003, Urology.

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

John F. Karpovich, Andrew S. Grimshaw, HyungJun Cho, 2008 .

Pilot experience with real-time ultrasound guided percutaneous renal mass cryoablation.

Dan Theodorescu, D. Theodorescu, Yan Moore, 2004, The Journal of urology.

Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis*

Harald Mischak, Mohammed Dakna, Marion Haubitz, 2009, Molecular & Cellular Proteomics.

Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer

Garrett M. Dancik, Dan Theodorescu, G. Dancik, 2017, Molecular Cancer Research.

Learning therapeutic lessons from metastasis suppressor proteins

Dan Theodorescu, D. Theodorescu, Steven C. Smith, 2009, Nature Reviews Cancer.

TERT promoter mutations and telomerase reactivation in urothelial cancer

James C. Costello, Garrett M. Dancik, Dan Theodorescu, 2015, Science.

RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Dan Theodorescu, D. Theodorescu, N. Said, 2012, The Journal of clinical investigation.

Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.

Dan Theodorescu, Mark Smolkin, H. Frierson, 2009, The American journal of pathology.

Prediction of drug combination chemosensitivity in human bladder cancer

Jae K. Lee, Jae K Lee, HyungJun Cho, 2007, Molecular Cancer Therapeutics.

GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.

Garrett M. Dancik, Dan Theodorescu, James C Costello, 2016, Cancer research.

Perioperative costs and charges of prostate brachytherapy and prostatectomy.

Dan Theodorescu, D. Theodorescu, James C Boyd, 2002, Urology.

Prostatourethral-rectal fistula after prostate brachytherapy: Incidence and risk factors

Dan Theodorescu, Jay Y. Gillenwater, Panos G. Koutrouvelis, 2000 .

Angiogenesis in Prostate Cancer: Biology and Therapeutic Opportunities

Greg Schaefer, Greg P. Schaefer, Dan Theodorescu, 2004, Cancer and Metastasis Reviews.

Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer

Zhiming Cai, Garrett M. Dancik, Dan Theodorescu, 2014, Clinical Cancer Research.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

Gary L. Gallia, Arthur P. Grollman, Tian-Li Wang, 2013, Proceedings of the National Academy of Sciences.

Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry

Jae K Lee, Hyungjun Cho, Klaus Ley, 2007, Proteomics.

Angiogenesis and prostate cancer tumor growth

Dan Theodorescu, D. Theodorescu, B. Nicholson, 2004, Journal of cellular biochemistry.

The faces and friends of RhoGDI2

Dan Theodorescu, D. Theodorescu, Erin M. Griner, 2012, Cancer and Metastasis Reviews.

Utilizing the molecular gateway: the path to personalized cancer management.

Jae K. Lee, Jae K Lee, Dan Theodorescu, 2009, Clinical chemistry.

Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer

Dan Theodorescu, M R Conaway, L. Sapinoso, 2004, Clinical Cancer Research.

Discovery and characterization of small molecules that target the GTPase Ral

David L. Brautigan, Samy O. Meroueh, Degang Liu, 2014, Nature.

CD24 is an effector of HIF-1-driven primary tumor growth and metastasis.

Glen Kristiansen, Dan Theodorescu, H. Frierson, 2012, Cancer research.

Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation

Shahrokh F. Shariat, Michael S. Cookson, Xue-Ru Wu, 2012, PloS one.

Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.

Jae K. Lee, Stefan Bekiranov, Dan Theodorescu, 2011, Neoplasia.

Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors.

Dan Theodorescu, Ann Gill Taylor, Cheryl Bourguignon, 2007, Oncology nursing forum.

Prognostic Markers in Localized Prostate Cancer: From Microscopes to Molecules

Dan Theodorescu, D. Theodorescu, Michael A. Harding, 1998, Cancer and Metastasis Reviews.

The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations

Russell Bowler, George A. Calin, Simona Rossi, 2014, Nucleic acids research.